Sharemaestro Newsreel

EVT.D.DX Price History for Evotec Se Stock

This article provides a comprehensive overview of the price history for Evotec Se (EVT.D.DX) stock on Barchart.com. It details how users can access and download historical daily, intraday, weekly, monthly, and quarterly price data, as well as information on corporate actions like splits and …

Cronos Group (TSX:CRON) - Stock Analysis

This article provides a detailed stock analysis of Cronos Group (TSX:CRON), a cannabinoid company, covering its valuation, growth prospects, financial health, and recent news. It highlights the company's market capitalization, forecasted earnings growth, and recent product launches and financial performance. The analysis also includes …

Tilray Brands climbs 8%, extending prior day's gains (TLRY:NASDAQ)

Tilray Brands (TLRY) shares climbed over 8% on Friday, extending a 5% gain from the previous day. This surge follows the global cannabis and beverage company's recent quarterly results. Despite the positive stock movement, investor concerns remain regarding recurring share dilution and management credibility.

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S

Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling …

Aurora Cannabis Inc. stock falls Friday, underperforms market

Aurora Cannabis Inc. (ACB) stock dropped 1.41% on Friday, closing at $2.79, despite a positive overall trading day for the broader market. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains, indicating that Aurora Cannabis underperformed its peers. This decline ended …

Viatris Inc. stock falls Friday, underperforms market

Viatris Inc. (VTRS) stock fell 1.13% on Friday, closing at $17.56, despite an overall positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for Viatris …

Canopy Growth Number of Employees 2026 | Employee Count & Headcount Data

Canopy Growth Corp. (WEED) had approximately 1,140 employees worldwide as of March 2026, representing a 23.7% decline since 2023. The company is actively hiring with 106 active job postings in 2026, despite a 13.2% decline from 2025. Canopy Growth's workforce is primarily located in …

BioXcel Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. This action follows BioXcel's disclosure that a principal …

Opaleye Management (NASDAQ: HROW) discloses 6.44% Harrow ownership in latest filing

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, has reported a beneficial ownership of 6.44% in Harrow, Inc.'s Common Stock, totaling 2,400,000 shares. This disclosure was made in a SCHEDULE 13G/A filing and is based on 37,275,107 shares outstanding as of May …

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

Liquidia Corporation (LQDA) is set to release its Q2 earnings on August 12, with strong sales and EPS estimates. The company has a positive earnings surprise history and its Yutrepia inhalation powder is a key growth driver, with impressive adoption rates. Despite competition, especially …

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Tilray Brands (NASDAQ:TLRY) shares rise, driven by growth in beverages and distribution

Tilray Brands (NASDAQ:TLRY) shares climbed by 6.4% to $4.47, fueled by significant growth in its beverage and distribution segments which accounted for 89% of revenue growth in the fourth quarter. While non-cannabis operations drove 71% of yearly revenue, cannabis contributed a larger share of …

Evotec stock trades steady as recent earnings and cash position frame the outlook

Evotec's stock performance is influenced by its solid revenue growth, recent net losses, and substantial cash reserves. The biotech company, listed on Xetra, saw double-digit revenue growth in fiscal 2025 but also reported a net loss due to high operating costs and investments in …

Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ)

Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) experienced significant declines after Novo Nordisk's (NVO) late-stage trial setback cast doubt on the mechanisms underlying their experimental heart disease therapies. The failure of Novo Nordisk's drug, which targeted hsCRP, raised questions about whether …

Analysts Have Conflicting Sentiments on These Healthcare Companies: Takeda Pharmaceutical Company (TAK), Align Tech (ALGN) and Conmed (CNMD)

This article summarizes recent analyst ratings for three healthcare companies: Takeda Pharmaceutical Company (TAK), Align Tech (ALGN), and Conmed (CNMD). Bank of America Securities maintained a Buy rating on Takeda, while giving Sell ratings to Align Tech and Conmed, highlighting conflicting sentiments within the …

Perrigo Co. PLC stock underperforms Friday when compared to competitors

Perrigo Co. PLC (PRGO) stock fell 1.94% on Friday, closing at $10.11, despite an overall positive trading session for the broader market. This marks the second consecutive day of losses for the company, while the S&P 500 and Dow Jones Industrial Average both saw …

Cronos Group Inc. stock falls Friday, underperforms market

Cronos Group Inc. (CRON) shares fell by 2.08% to $2.83 on Friday, despite a strong overall market performance where the NASDAQ Composite Index and Dow Jones Industrial Average both rose. This decline ended a two-day winning streak for the stock.

12 Health Care Stocks Moving In Friday's Intraday Session

This article identifies 12 healthcare stocks that experienced significant movement during Friday's intraday trading session. It highlights both gainers, such as Replimune Group and SCYNEXIS, which saw substantial increases, and losers like Karyopharm Therapeutics and Nuwellis, which experienced notable declines. The report provides specific …

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs (NASDAQ: BIOA) stock significantly dropped after Novo Nordisk's ZEUS trial results for ziltivekimab, an experimental drug, failed to reduce major adverse cardiovascular events. This outcome has led William Blair analyst Andy Hsieh to question the link between hsCRP reduction and cardiovascular protection, …

SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of SCYNEXIS Inc (SCYX), reporting its current financial score as 9.29, ranking 3 out of 155 in the Pharmaceuticals industry. The company's financial status is described as robust with high operating efficiency, despite a significant year-over-year decrease …

BioAge Labs Down Over 61%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

BioAge Labs, Inc. (BIOA) is experiencing a significant downturn, with its stock price at $9.61, representing a 61.33% decrease. This puts the company on track for its largest percentage decrease since December 2024 and its worst weekly and monthly performance since the same period. …

Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside

Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. …

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal Pharmaceuticals MDGL reported second-quarter 2026 loss of $1.99 per share, narrower than the Zacks Consensus Estimate of a loss of $2.55. In the same quarter last year, the company had incurred a loss of $1.50 per share. In the second quarter, MDGL generated …

Lantheus Holdings (LNTH): Vanguard Portfolio Management reports 5.06% ownership stake

Vanguard Portfolio Management has reported a 5.06% ownership stake in Lantheus Holdings Inc. (LNTH) through a Schedule 13G SEC filing. This filing indicates beneficial ownership of 3,300,293 shares as of June 30, 2026, with Vanguard holding sole voting power over 61,822 shares and sole …

Vanguard Capital Management (XERS) discloses 8.64M-share, 5% holding in Xeris

Vanguard Capital Management LLC and its affiliates have reported a 5% beneficial ownership stake in Xeris Biopharma Holdings Inc, amounting to 8,637,640 common shares. This disclosure, made via a Schedule 13G filing, indicates that Vanguard holds sole voting power over 1,297,411 shares and sole …

Vanguard Capital Management (DERM) discloses 774,556 Journey Medical shares in 13G/A

Vanguard Capital Management has filed an amended Schedule 13G/A, disclosing beneficial ownership of 774,556 shares of Journey Medical Corp common stock, which represents 3.59% of the class. Vanguard has sole voting power over 99,371 shares and sole dispositive power over all 774,556 shares. The …

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.63, Implies 13% Upside

Neurocrine Biosciences, Inc. (NBIX) has seen its average 12-month stock price target increased from $201.2 to $209.34 by 28 analysts, implying a potential 13% upside based on the July 30 closing price. The consensus rating among 31 covering analysts remains a "Buy," with 27 …

Vanguard Capital Management (ANIK) discloses 4.95% beneficial stake in Anika Therapeutics

Vanguard Capital Management LLC has reported a 4.95% beneficial ownership stake in Anika Therapeutics Inc (ANIK), amounting to 659,216 shares as of June 30, 2026. The filing indicates that Vanguard holds sole voting power over 87,103 shares and sole dispositive power over all 659,216 …

Vanguard Capital Management (COLL) discloses 5.01% passive stake in Collegium

Vanguard Capital Management LLC has disclosed a passive stake of 5.01% in Collegium Pharmaceutical Inc. common stock, totaling 1,625,821 shares, through a Schedule 13G filing. Vanguard holds sole voting power over 244,560 shares and sole dispositive power over all 1,625,821 shares. This filing aggregates …

Vanguard Capital Management (EBS) discloses 4.92% Emergent BioSolutions ownership

Vanguard Capital Management LLC and its affiliates have reported a beneficial ownership of 2,540,945 shares of Emergent BioSolutions Inc. common stock, which constitutes 4.92% of the total class as of June 30, 2026. This Schedule 13G/A filing indicates that Vanguard has sole voting power …

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI Pharmaceuticals (ANIP) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026. Despite a positive Earnings ESP, the stock's Zacks Rank #4 makes it difficult to definitively predict an earnings beat. Investors are advised to …

BIOAGE LABS INC : NEEDHAM CUTS TARGET PRICE TO $35 FROM $50

Needham has cut its target price for BIOAGE LABS INC (BIOA.O) shares to $35 from the previous $50. This information was reported by Reuters on July 31, 2026. The article advises readers that the content reflects only the author's opinion and is not investment …

Haleon plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:HLN) 2026-07-30

Haleon plc has published its slide deck in conjunction with its Q2 2026 earnings call. This presentation provides details relevant to the company's financial performance for the quarter ending July 30, 2026. The information is made available to investors following the earnings call.

BHC Stock Soars As Earnings Beat Fuels Fresh Uptrend

Bausch Health Companies Inc. (BHC) saw its stock jump by 11.53% due to strong Q2 2026 earnings, beating analyst expectations for both EPS and revenue. This marks the 13th consecutive quarter of revenue and adjusted EBITDA growth for the company, signaling a significant turnaround …

Guggenheim raises Neurocrine Bio stock price target on Ingrezza beat

Guggenheim has increased its price target for Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares to $222 from $200, maintaining a Buy rating after the company's strong second-quarter results. The company reported Ingrezza sales significantly above consensus and raised its full-year 2026 Ingrezza sales guidance, driven by …